Gilead Prices Novel Cancer Therapy at $373,000 After Approval

Gilead Sciences Inc. won approval from regulators for a personalized blood cancer treatment a month earlier than expected, a key first step as the company tries to shift its business into the oncology field.

The therapy, called Yescarta, is made via a complicated process that involves extracting a patient’s immune system cells and modifying them to attack blood cancers. Yescarta will cost $373,000, a list price that doesn’t include related care and is in line with what most analysts anticipated. It is only the second drug in a breakthrough category known as CAR-T to have gained approval.

Gilead, which made ...